SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if treatment with atezolizumab and stereotactic body
radiation therapy (SBRT) will improve the objective response rate (ORR) compared with
atezolizumab alone in patients with recurrent, persistent, or metastatic cervical cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute